4974.T
TAKARA BIO INC.
プライム · 化学 · 素材・化学 · JP
JPY 1,144.00
+0.09%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 40.3B | 40.3B | 45.0B | 43.5B | 78.1B |
| Cost of Revenue | 4.3B | 20.1B | 19.0B | 16.6B | 33.4B |
| Gross Profit | 5.0B | 20.3B | 26.1B | 26.9B | 44.8B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 6.8B | 24.9B | 23.8B | 23.9B | 24.2B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 6.8B | 24.9B | 23.8B | 23.9B | 24.2B |
| Cost and Expenses | 45.0B | 45.0B | 42.8B | 40.5B | 57.6B |
| Operating Income (EBIT) | (4.7B) | (4.7B) | 2.3B | 3.0B | 20.5B |
| Non-Operating | |||||
| Interest Income | 50.0M | 174.0M | 300.0M | 186.0M | 142.0M |
| Interest Expense | 117.0M | 582.0M | 20.0M | 23.0M | 24.0M |
| Net Interest Income | (67.0M) | (408.0M) | 280.0M | 163.0M | 118.0M |
| Other Non-Op Income/Expense | (42.0M) | (305.0M) | 330.0M | 402.0M | 142.0M |
| Non-Operating Income (excl Interest) | 55.0M | 253.0M | 319.0M | 327.0M | 221.0M |
| EBT (Pre-Tax Income) | (1.8B) | (9.2B) | 2.0B | 2.9B | 21.2B |
| Income Tax Expense | (289.0M) | 353.0M | 910.0M | 1.3B | 5.2B |
| Bottom Line | |||||
| Net Income | (9.6B) | (9.6B) | 1.0B | 1.5B | 16.0B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (9.6B) | (9.6B) | 1.0B | 1.5B | 16.0B |
| Per Share | |||||
| Basic EPS | (¥80) | (¥80) | ¥9 | ¥12 | ¥133 |
| Diluted EPS | (¥80) | (¥80) | — | — | — |
| Revenue Per Share | ¥335 | ¥335 | ¥374 | ¥361 | ¥649 |
| Shares | |||||
| Basic Shares Outstanding | 120.4M | 120.4M | 120.4M | 120.4M | 120.4M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | (750.0M) | (552.0M) | 5.9B | 7.3B | 24.6B |
| D&A | 1.0B | 4.1B | 3.6B | 4.3B | 4.0B |
| EBIT | (4.7B) | (4.7B) | 2.3B | 3.0B | 20.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026